Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BARS13 RSV Vaccine in Healthy Adults
NCT04851977Phase 1Completed
- Sponsor
- Advaccine Biotechnology
- Start
- Oct 2018
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BARS13 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Advaccine Biotechnology. Primary endpoints: Incidence of systemic reactions, Incidence of local reactions and 4 more. Started Oct 2018; status: completed.
02
Drugs
BARS13
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04851977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851977.